COVID Vaccine-Associated Uveitis
PURPOSE: Following the pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2, different vaccines were developed and approved by the main medical authorities under emergency protocol regulations. Although highly effective and well-tolerated in most patients, vaccines can uncommonly cause ocular adverse effects. In this article, the current evidence related to vaccine-associated uveitis is reviewed.
METHODS: A literature review of uveitis post various SARS-CoV-2 vaccinations.
RESULTS: Uveitis was reported following various forms of vaccinations but was more commonly seen following the Pfizer mRNA vaccine which is the most used vaccination worldwide. In western countries, the most common uveitis is mild anterior uveitis, developing within a week of first or subsequent vaccination with good resolution following appropriate topical steroid therapy in most cases. Posterior uveitis and particularly Vogt-Koyanagi-Harada disease was more prevalent in Asia. Uveitis may develop among known uveitis patients and those with other autoimmune diseases.
CONCLUSION: Uveitis following Covid vaccinations is uncommon and has a good prognosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Ocular immunology and inflammation - 31(2023), 6 vom: 05. Aug., Seite 1198-1205 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Habot-Wilner, Zohar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID vaccination |
|---|
| Anmerkungen: |
Date Completed 02.08.2023 Date Revised 02.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/09273948.2023.2200858 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356484068 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356484068 | ||
| 003 | DE-627 | ||
| 005 | 20231226070547.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/09273948.2023.2200858 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1188.xml |
| 035 | |a (DE-627)NLM356484068 | ||
| 035 | |a (NLM)37145198 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Habot-Wilner, Zohar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID Vaccine-Associated Uveitis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.08.2023 | ||
| 500 | |a Date Revised 02.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: Following the pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2, different vaccines were developed and approved by the main medical authorities under emergency protocol regulations. Although highly effective and well-tolerated in most patients, vaccines can uncommonly cause ocular adverse effects. In this article, the current evidence related to vaccine-associated uveitis is reviewed | ||
| 520 | |a METHODS: A literature review of uveitis post various SARS-CoV-2 vaccinations | ||
| 520 | |a RESULTS: Uveitis was reported following various forms of vaccinations but was more commonly seen following the Pfizer mRNA vaccine which is the most used vaccination worldwide. In western countries, the most common uveitis is mild anterior uveitis, developing within a week of first or subsequent vaccination with good resolution following appropriate topical steroid therapy in most cases. Posterior uveitis and particularly Vogt-Koyanagi-Harada disease was more prevalent in Asia. Uveitis may develop among known uveitis patients and those with other autoimmune diseases | ||
| 520 | |a CONCLUSION: Uveitis following Covid vaccinations is uncommon and has a good prognosis | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID vaccination | |
| 650 | 4 | |a SARS-Cov-2 vaccine-associated uveitis | |
| 650 | 4 | |a SARS-Cov-2 vaccines | |
| 650 | 4 | |a mRNA COVID vaccine | |
| 650 | 4 | |a uveitis | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Neri, Piergiorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Annabelle A |e verfasserin |4 aut | |
| 700 | 1 | |a Agrawal, Rupesh |e verfasserin |4 aut | |
| 700 | 1 | |a Xin Le, Ng |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Shai |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, Naomi |e verfasserin |4 aut | |
| 700 | 1 | |a Kilmartin, Fionn |e verfasserin |4 aut | |
| 700 | 1 | |a Coman, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Kilmartin, Dara |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ocular immunology and inflammation |d 1993 |g 31(2023), 6 vom: 05. Aug., Seite 1198-1205 |w (DE-627)NLM091014069 |x 1744-5078 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2023 |g number:6 |g day:05 |g month:08 |g pages:1198-1205 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/09273948.2023.2200858 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2023 |e 6 |b 05 |c 08 |h 1198-1205 | ||